Safety considerations of recombinant protein therapy: introductory comments
Clin Immunol Immunopathol
.
1997 Apr;83(1):1-4.
doi: 10.1006/clin.1996.4301.
Authors
T J Hayes
1
,
B Ryffel
Affiliation
1
Hoffmann-La Roche Inc., Nutley, New Jersey 07110-1199, USA.
PMID:
9073524
DOI:
10.1006/clin.1996.4301
No abstract available
Publication types
Comment
Review
MeSH terms
Animals
Antibody Formation
Humans
Interleukin-3 / immunology
Recombinant Proteins / standards*
Recombinant Proteins / therapeutic use*
Substances
Interleukin-3
Recombinant Proteins